T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
about
Developing strategies in the immunotherapy of leukemiasAdoptive T-cell therapy for LeukemiaActive specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trialsStructures of native and affinity-enhanced WT1 epitopes bound to HLA-A0201: Implications for WT1-based cancer therapeuticsDevelopment of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID miceImmune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Immunotherapy in acute leukemiaThe cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors.Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationDoes chemotherapy modify the immune surveillance of hematological malignancies?Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation.Improving the safety of cell therapy products by suicide gene transferWilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer.Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.Detection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantT-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyImproved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4(+) and CD8(+) memory formation.Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia.Reactivation of Silenced WT1 Transgene by Hypomethylating Agents - Implications for in vitro Modeling of Chemoimmunotherapy.Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias.Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies.Targeting tumours by adoptive transfer of immune cells.Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.T cell therapy in allogeneic stem cell transplantation.Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia.Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia.Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation.Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunityThe biological basis for immunotherapy in patients with chronic myelogenous leukemia.The allogeneic graft-versus-cancer effect.WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.
P2860
Q26996310-841EA86B-BDE0-468F-BFA0-FA5BB80CAD8FQ27006934-84535816-E10B-4319-B6B3-3510FAC193ADQ27026836-B788A671-AC96-40CC-9412-70CD0EB67765Q27663300-049270E3-14EF-4C05-AD6D-D1B76E2C643BQ33587590-37EAC973-18D3-4B49-97B7-BB6DC2C367ACQ33593877-0732F186-831C-491C-9BE2-473705B85CFDQ33731552-E300044E-6033-4049-B7BB-A9A21D18B8ECQ33847461-7FE70E37-6D18-4627-B819-303933ADD072Q34022415-75CB0175-5597-4D67-BC44-03D4E520C11DQ34068404-108974C3-7300-43E8-82CE-1EBC7C301DD4Q34223517-791D1182-DEBB-480C-81A8-7FE811ECF0B7Q34279672-679B6004-5EB5-4790-881E-42B5E1838B01Q34453846-474CC304-2623-4C5D-920D-4CCC813CD324Q34498299-FBBC5FD4-3062-49EF-B078-ED6BD9DBACDEQ34612637-F5A4ED5F-7797-46A3-BBFB-1A5723EE9547Q34616701-1C969CEA-12B7-40BC-9132-6CC4DE014377Q34617770-7EE3C774-A6EE-41D7-8630-6A367DF63730Q34635978-B59A01DC-42E7-4602-8CAB-C1FDFC98BF79Q34707452-F9BFEEF6-2FAB-4C52-95B1-024749FC8EDDQ34792248-B52B0FB9-309F-4738-9222-EE01763C6E90Q34803707-E93967A1-BD10-4DA2-96E4-E61F90830EAAQ35634680-B0C18973-E758-4612-99F6-9482770F5DD1Q35711576-C09E5A93-FE13-4A65-82A7-E3558261A5FCQ35889240-140FA292-E604-48AF-9F4F-536A3334C3BDQ35990687-9FD0195D-616B-49E4-A393-33FA70FD5132Q36056904-18426A67-A405-43A3-806D-21466CA32143Q36194241-DD515B54-3427-4B45-9AE2-E286410D6062Q36384606-D3B751FC-A897-4DB5-BB94-012438036D12Q36478870-BB810736-45B8-4382-9413-DAF495F9B5E3Q36793112-4E9D3B74-883C-4810-B664-235172154001Q36952252-1B150015-D497-4C88-A6A8-96BF14F80312Q37045973-293E0661-1C63-4848-8EE3-6CBE5D3A488FQ37088532-740AF815-3A31-428D-8445-BE68DEC3B76BQ37119922-BFB64682-A89C-47EF-990F-5311B0FB40B6Q37132892-95EA730F-8F03-41DB-B4F4-B108F3901D33Q37159243-61DC98BB-C2A1-4BF4-87B5-4010D23B9AF8Q37428671-9196DEB7-D495-430E-828B-FB3EB9776408Q37593125-A39BD67D-6A00-4CDC-A935-17D373A5AFE2Q37635023-0BC7325E-8F67-4ACF-ACA0-0D671B56FCA1Q37707135-7B82A3BB-0A38-4166-91F9-F0A9F235541B
P2860
T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms' tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
T-cell responses directed agai ...... ication, and characterization.
@en
type
label
T-cell responses directed agai ...... ication, and characterization.
@en
prefLabel
T-cell responses directed agai ...... ication, and characterization.
@en
P2093
P50
P1476
T-cell responses directed agai ...... ication, and characterization.
@en
P2093
A John Barrett
Daniel C Douek
Emma Gostick
Jason M Brenchley
Jongming Li
Katayoun Rezvani
Yasemin Kilical
P304
P356
10.1158/1078-0432.CCR-05-1314
P407
P433
P577
2005-12-01T00:00:00Z